Shopping Cart
Remove All
Your shopping cart is currently empty
Crizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $239 | - | In Stock | |
| 5 mg | $787 | - | In Stock | |
| 10 mg | $1,320 | - | In Stock | |
| 25 mg | $1,960 | - | In Stock | |
| 50 mg | $2,650 | - | In Stock |
| Description | Crizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease. |
| In vivo | 'Crizanlizumab (1 or 6 mg/kg; intraperitoneal injection; three times a week; for 5 months) improves sickle cell retinopathy in 4-week-old male HbSS (sickle cell disease) mice[2].' |
| Synonyms | SEG-101, ADAKVEO |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 150 kDa |
| Cas No. | 1690318-25-2 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.